Surovatamig Clinical Trials

4 actively recruiting trials across 4 locations

No change since May 2026

Also known as: AZD0486, TNB-486

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

AstraZeneca4

Indications

Cancer3
B-Cell Non-Hodgkin Lymphoma2
Large B-Cell Lymphoma (LBCL)1
Systemic Lupus Erythematosus1
Untreated Follicular Lymphoma1

Birmingham, Alabama1 trial

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Research Site

Phase 1

Huntsville, Alabama1 trial

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Research Site

Phase 3

Phoenix, Arizona1 trial

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Research Site

Phase 2

Boston, Massachusetts1 trial

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.